Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 1 , Pages 167-176 , March 2008

Brain protection: Current and future options

  • Jane Sturgess, MBBS FRCA MRCP (Specialist Registrar)
    • ,
  • Basil Matta, MA FRCA (Clinical Director and Consultant in Anaesthesia and NeuroCritical Care)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +01223 245151.

References 

  1. Ferrer I. Apoptosis: future targets for neuroprotective strategies. Cerebrovascular Diseases. 2006;21(suppl 2):9–20
  2. Busija DW, Lacza Z, Rajapakse N, et al. Targeting mitochondrial AT-sensitive potassium channels – a novel approach to neuroprotection. Brain Research Reviews. 2004;46:282–294
  3. Chiarugi A. Poly(ADP-ribosyl)ation and stroke. Pharmacological Research. 2005;52:15–24
  4. Leira R, Blanco M, Rodriguez-Yanez M, et al. Non-pharmacological neuroprotection: role of emergency stroke management. Cerebrovascular Diseases. 2006;21(suppl 2):89–98
  5. Van den Bergh G, Wouters P, Weckers F, et al. Intensive insulin therapy in critically ill patients. The New England Journal of Medicine. 2001;345:1359–1367
  6. Anderson RE, Tan WK, Martin HS, et al. Effects of glucose and PO2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischaemic penumbra. Stroke. 1999;30:160–170
  7. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426–2432
  8. Scott JF, Robinson GM, French JM, et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycaemia. The Glucose Insulin in Stroke Trial (GIST). Stroke. 1999;30:793–799
  9. Olsen TS, Weber UJ, Kammersgaard LP. Therapeutic hypothermia for acute stroke. Lancet Neurology. 2003;2:410–416
  10. Hajat C, Hajat S, Sharma P. Effects of post-stroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke. 2000;31:410–414
  11. Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. The New England Journal of Medicine. 2002;346:549–556
  12. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature. 1994;367:607–614
  13. Kudo M, Aono M, Lee Y, et al. Effects of volatile anaesthetics on N-methyl-D-aspartate toxicity in primary rat neuro-glial cultures. Anesthesiology. 2001;95:756–765
  14. Statler KD, Kochanek PM, Dixon , et al. Isoflurane improves long-term neurological outcome versus fentanyl after traumatic brain injury in rats. Journal of Neurotrauma. 2000;17:1179–1189
  15. Bickler PE, Zhan X, Fahlman CS, et al. Isoflurane preconditions hippocampal neurons against oxygen-glucose deprivation: the role of intracellular Ca2+ and mitogen-activated protein kinase signalling. Anesthesiology. 2005;103:532–539
  16. Ma D, Hossain M, Rajakumaraswamy N, et al. Combination of xenon and isoflurane produces a synergistic protective effect against oxygen-glucose deprivation injury in a neuronal-glial co-culture model. Anesthesiology. 2003;99:748–751
  17. Bickler PE, Warner DS, Stratmann G. Gamma-Aminobutyric acid-A receptors contribute to isoflurane neuroprotection in organotypic hippocampal cultures. Anesthesia & Analgesia. 2003;97:564–571
  18. Zhan X, Fahlman CS, Bickler PE. Isoflurane neuroprotection in rat hippocampal slices decreases with aging: changes in intracellular Ca2+ regulation and N-methyl-D-aspartate receptor-mediated Ca2+ influx. Anesthesiology. 2006;104:995–1003
  19. Payne RS, Akca O, Roewer N, et al. Sevoflurane-induced preconditioning protects against cerebral ischaemic neuronal damage in rats. Brain Research. 2005;1034:147–152
  20. Haelewyn B, Yvon A, Hanouz JL, et al. Desflurane affords greater protection than halothane against focal cerebral ischaemia in the rat. British Journal of Anaesthesia. 2003;91:390–396
  21. Kawaguchi M, Furuya H, Patel PM. Neuroprotective effects of anesthetic agents. Journal of Anesthesia. 2005;19:150–156
  22. Adembri C, Venturi DJ, Tani A, et al. Neuroprotective effects of propofol in models of cerebral ischemia: inhibition of mitochondrial swelling as a possible mechanism. Anesthesiology. 2006;104:80–89
  23. Peters CE, Korcok J, Gelb AW, et al. Anesthetic concentrations of propofol protect against oxidative stress in primary astrocyte cultures: comparison with hypothermia. Anesthesiology. 2001;94:313–321
  24. Daskalopoulos R, Korcok J, Farhangkhgoee P, et al. Propofol protection of sodium-hydrogen exchange activity sustains glutamate uptake during oxidative stress. Anesthesia & Analgesia. 2001;93:1199–1204
  25. Proescholdt M, Heimann A, Kempski O. Neuroprotection of S(+) ketamine isomer in global forebrain ischaemia. Brain Research. 2001;904:245–251
  26. Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury?. Anesthesia & Analgesia. 2005;101:524–534
  27. Sanders RD, Maze M. Xenon: from stranger to guardian. Current Opinion in Anaesthesiology. 2005;18:405–411
  28. Ma D, Hossain M, Pettet GK, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. Journal of Cerebral Blood Flow and Metabolism. 2006;26:199–208
  29. David HN, Leveille F, Chazalviel L, et al. Reduction of ischaemic brain damage by nitrous oxide and xenon. Journal of Cerebral Blood Flow and Metabolism. 2003;23:1168–1173
  30. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Natural Medicines. 2004;4:460–463
  31. Cao H, Kass IS, Cottrell JE, et al. Pre or post insult administration of lidocaine or thiopental attenuates cell death in rat hippocampal slice cultures caused by oxygen-glucose deprivation. Anesthesia & Analgesia. 2005;101:1163–1169
  32. Niiyama S, Tanaka E, Tsuji S, et al. Neuroprotective mechanisms of lidocaine against in vitro ischemic insult of the rat hippocampal CA1 pyramidal neurons. Neurosciences Research. 2005;53:271–278
  33. Soriano SG, Anand KJ. Anesthetics and brain toxicity. Current Opinion in Anaesthesiology. 2005;18:293–297
  34. Chen HS, Lipton SA. The chemical biology of the clinically tolerated NMDA receptor antagonists. Journal of Neurochemistry. 2006;97:1611–1626
  35. Yurkewicz L, Weaver J, Balica L, et al. The effect of the selective NMDA receptor traxoprodil in the treatment of traumatic brain injury. Journal of Neurotrauma. 2005;22:1428–1443
  36. Maas AL, Murray G, Henney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo controlled, clinical trial. Lancet Neurology. 2006;5:38–45
  37. Muir KW. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Current Opinion in Pharmacology. 2006;6:53–60
  38. Furukawa T, Hoshino S, Kobayashi S, et al. The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral oedema and neurological motor deficits after experimental brain injury in rats. Journal of Neurotrauma. 2003;20:269–278
  39. Markgraf CG, Velayo NL, Johnson MP, et al. Six-hour window of opportunity for calpain inhibition in focal cerebral ischaemia in rats. Stroke. 1998;29:152–158
  40. Kupina NC, Nath R, Bernath EE, et al. The novel calpain inhibitor SJA6017 improves functional recovery after delayed administration in a mouse model of diffuse head injury. Journal of Neurotrauma. 2001;18:1229–1240
  41. Wang KKW. Calpain and caspase: can you tell the difference. Trends in Neurosciences. 2000;23:20–26
  42. Linton SD, Aja T, Armstrong RA, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. Journal of Medicinal Chemistry. 2005;48:6779–6782
  43. Kreuter M, Langer C, Kerkhoff C, et al. Stroke, myocardial infarction, acute and chronic inflammatory diseases; caspases and other apoptotic molecules as targets for drug development. Archivum Immunologiae et Therapiae Experimentalis (Warsz). 2004;52:141–155
  44. Irazuzta J, Pretzlaff RK, DeCourten-Myers G, et al. Dexamethasone decreases neurological sequelae and caspase activity. Intensive Care Medicine. 2005;31:146–150
  45. Muir JA, Lees KR, Ford I, et al. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial. Lancet. 2004;363:439–445
  46. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulphate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurology. 2007;6:29–38
  47. van den Heuvel C, Vink R. The role of magnesium in traumatic brain injury. Clinical Calcium. 2004;14:9–14
  48. Merenda A, Bullock R. Clinical treatments for mitochondrial dysfunctions after brain injury. Current Opinion in Critical Care. 2006;12:90–96
  49. Mazzeo AT, Kunene NK, Gilman CB, et al. Severe human traumatic brain injury, but not cyclosporine A treatment, depresses activated T lymphocytes early after injury. Journal of Neurotrauma. 2006;23:962–975
  50. Siren AL, Radyushkin K, Boretius S, et al. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain. 2006;129:480–489
  51. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoeitin therapy for acute stroke is both safe and beneficial. Molecular Medicine. 2002;8:495–505
  52. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. Journal of Neurosurgical Anesthesiology. 2006;18:132–138
  53. Hoffman GE, Merchenthaler I, Zup SL. Neuroprotection by ovarian hormones in animal models of neurological disease. Endocrine. 2006;29:217–232
  54. Dubal DB, Rau SW, Shugrue PJ, et al. Differential modulation of oestrogen receptors (ERs) in ischemic brain injury: a role for ER(alpha) in estradiol-mediated protection against delayed cell death. Endocrinology. 2006;147:3076–3084
  55. Pettus EH, Wright DW, Stein DG, et al. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. Brain Research. 2005;1049:112–119
  56. Robertson CL, Puskar A, Hoffman GE, et al. Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Experimental Neurology. 2006;197:235–243
  57. Stein DG, Hoffman SW. Estrogen and progesterone as neuroprotective agents in the treatment of acute brain injuries. Pediatric Rehabilition. 2003;6:13–22
  58. Djenaili M, Guo Q, Pettus EH, et al. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. Journal of Neurotrauma. 2005;22:106–118
  59. Wright DW, Kellerman AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Annals of Emergency Medicine. 2007;49:391–402
  60. Marmarou A, Guy M, Murphy L, et al. A single dose, three arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury. Journal of Neurotrauma. 2005;22:1444–1455
  61. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischaemic brain injury. Nature Chemical Biology. 2005;1:146–150
  62. Warner DS. Perioperative neuroprotection: are we asking the right questions?. Anesthesia & Analgesia. 2004;98:563–565
  63. AsatraZeneca International. AstraZeneca announces SAINT II Trial results showed no efficacy in acute ischaemic stroke. Available at: http://www.astrazeneca.com/pressrelease/5279.aspx.Released 26th October 2006.
  64. Ginsberg MD. Post-NXY-059 era ischemic neuroprotection. Stroke. 2007;6:1966–1972

PII: S1521-6896(07)00082-1

doi: 10.1016/j.bpa.2007.09.002

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 1 , Pages 167-176 , March 2008

Article Tools